A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous APL-2 in Healthy Adult Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous APL-2 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs APL 2 (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Acronyms APL-CP0713-1
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2016 Results (n=51) of APL-CP0713-1 and APL-CP1014 studies assessing safety, tolerability, pharmacokinetics and pharmacodynamics presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 21 Nov 2016 Data from this and another phase I trial (APL-CP1014) will be presented at the American Society of Hematology (ASH) Annual Meeting 2016, according to an Apellis Pharmaceuticals media release.
    • 23 Jun 2016 Results published in an Apellis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top